Valvular heart disease

Trisol announces successful implants of its Transcatheter Tricuspid Valve in the US

Retrieved on: 
Wednesday, August 23, 2023
University of Virginia Health System, University, TR, Food and Drug Administration, Cardiopulmonary bypass, Risk, Valvular heart disease, EFS, Principal, Food, Medical device, Trisol, MD

YOKNEAM, Israel, Aug. 23, 2023 /PRNewswire/ -- The heart teams at the Piedmont Heart Institute in Atlanta, Georgia, USA and the University of Virginia Health System in Charlottesville, VA, USA, successfully performed the first two implantations in the US of the Trisol Transcatheter Tricuspid Valve Replacement as part of a U.S. Food and Drug Administration approved Early Feasibility Study (EFS), led by Principal Investigator Isaac George, MD.

Key Points: 
  • We were able to abolish the patient's valvular heart disease via a minimally invasive procedure without the need for cardiopulmonary bypass.
  • Trisol patented valve features a distinctive design, that sets it apart from other tricuspid valves technologies.
  • Trisol valve is comprised of a single leaflet, the leaflet is affixed by 2 commissures enabling it to function as a bi-leaflet valve.
  • Five of these implants were performed as part of the Israeli Pilot Study, led by Principal Investigator Ran Kornowski, MD.

Trisol announces successful implants of its Transcatheter Tricuspid Valve in the US

Retrieved on: 
Wednesday, August 23, 2023
University of Virginia Health System, University, TR, Food and Drug Administration, Cardiopulmonary bypass, Risk, Valvular heart disease, EFS, Principal, Food, Medical device, Trisol, MD

YOKNEAM, Israel, Aug. 23, 2023 /PRNewswire/ -- The heart teams at the Piedmont Heart Institute in Atlanta, Georgia, USA and the University of Virginia Health System in Charlottesville, VA, USA, successfully performed the first two implantations in the US of the Trisol Transcatheter Tricuspid Valve Replacement as part of a U.S. Food and Drug Administration approved Early Feasibility Study (EFS), led by Principal Investigator Isaac George, MD.

Key Points: 
  • We were able to abolish the patient's valvular heart disease via a minimally invasive procedure without the need for cardiopulmonary bypass.
  • Trisol patented valve features a distinctive design, that sets it apart from other tricuspid valves technologies.
  • Trisol valve is comprised of a single leaflet, the leaflet is affixed by 2 commissures enabling it to function as a bi-leaflet valve.
  • Five of these implants were performed as part of the Israeli Pilot Study, led by Principal Investigator Ran Kornowski, MD.

GENIXUS Announces Launch of KinetiXTM Rocuronium Bromide Injection 5mL & 10mL Ready-to-Administer Syringes

Retrieved on: 
Thursday, August 3, 2023
Medical Supplies, FDA, Hospitals, Clinical Trials, Biotechnology, Other Health, Managed Care, Health, Pharmaceutical, Hypersensitivity, Patient, Neuromuscular blocking agents, Kinetix, ECG, Rocuronium bromide, Multimedia, Chronic pain, Cosmetic, CCO, QT interval, Paralysis, Federal Food, Drug, and Cosmetic Act, Anaphylaxis, Valvular heart disease, Propofol, Hubli railway division, Nursing care plan, Relaxation, Pulmonary hypertension, Syringe, FD, Consciousness, Pfizer, Pharmaceutical industry, Nursing

View the full release here: https://www.businesswire.com/news/home/20230803139911/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230803139911/en/
    KinetiX Propofol & Rocuronium Bromide Injection RTA Syringes.
  • KinetiX Rocuronium Bromide Injection possesses several key attributes inherent in the KinetiX platform:
    GENIXUS' Chief Commercial Officer (CCO), Seth Coombs , emphasized the company's determination to accelerate the launch of Rocuronium Bromide Injection to address the ongoing, and expected worsening, of shortages in the US market.
  • If rocuronium bromide injection is administered via the same infusion line that is also used for other drugs, it is important that this infusion line is adequately flushed between administration of rocuronium bromide injection and drugs for which incompatibility with rocuronium bromide injection has been demonstrated or for which compatibility with rocuronium bromide injection has not been established.
  • Rocuronium bromide is contraindicated in patients known to have hypersensitivity (e.g., anaphylaxis) to rocuronium bromide or other neuromuscular blocking agents.

Biological Tissue Valve Segment Surges in the Global Transcatheter Heart Valve Market, Projected to Witness Rapid Growth by 2030

Retrieved on: 
Friday, July 28, 2023
Prevalence, Health, Ageing, Research, TAVI, Aortic stenosis, Percutaneous aortic valve replacement, Patient, Physician, Risk, Tissue engineering, Aortic valve, TAVR, Growth, Abdominal ultrasonography, Valvular heart disease, Medical device, Medical imaging

Aortic stenosis, a condition characterized by the incomplete opening of the aortic valve, has driven the need for transcatheter aortic valve implantation.

Key Points: 
  • Aortic stenosis, a condition characterized by the incomplete opening of the aortic valve, has driven the need for transcatheter aortic valve implantation.
  • Transcatheter Aortic Valve Replacement (TAVR) has emerged as the leading procedure in the global medical market, capturing the highest market share.
  • Rapid Growth of Biological Tissue Market Segment:
    Within the Transcatheter Aortic Valve Replacement (TAVR) industry, the biological tissue market is experiencing rapid growth and emerging as the fastest-growing segment.
  • In conclusion, the global transcatheter heart valve market is set for significant growth, reaching an estimated value of US$ 15.14 Billion by 2030.

Global Transcatheter Heart Valve Market Set to Reach $15.14 Billion by 2030 with a Strong CAGR of 12.73% - ResearchAndMarkets.com

Retrieved on: 
Friday, July 28, 2023
Research, Medical Devices, Technology, Hospitals, Health Technology, Science, Surgery, Cardiology, Biotechnology, Other Technology, Other Science, Health, Prevalence, Ageing, TAVI, Aortic stenosis, Percutaneous aortic valve replacement, Patient, Physician, Risk, Tissue engineering, Aortic valve, TAVR, Growth, Abdominal ultrasonography, Valvular heart disease, Medical device, Medical imaging

Aortic stenosis, a condition characterized by the incomplete opening of the aortic valve, has driven the need for transcatheter aortic valve implantation.

Key Points: 
  • Aortic stenosis, a condition characterized by the incomplete opening of the aortic valve, has driven the need for transcatheter aortic valve implantation.
  • The rising prevalence of aortic stenosis, along with improved surgical techniques and growing demand for surgical technologies, is propelling the transcatheter aortic valve replacement (TAVR) market.
  • Transcatheter Aortic Valve Replacement (TAVR) has emerged as the leading procedure in the global medical market, capturing the highest market share.
  • In conclusion, the global transcatheter heart valve market is set for significant growth, reaching an estimated value of US$ 15.14 Billion by 2030.

Eko Health Recognized for Award-Winning AI Technology and Hybrid Workforce

Retrieved on: 
Tuesday, May 23, 2023
VHD, Heart, Continuous noninvasive arterial pressure, Culture, Cardiovascular disease, Health, Creativity, Patient, Valvular heart disease, AI, FDA, 100 Best Workplaces in Europe, Nursing, Pharmaceutical industry, Data

OAKLAND, Calif., May 23, 2023 /PRNewswire/ -- Eko Health, a leading innovator in digital health technology for heart and lung disease detection, today announced that it has been honored in Fast Company's World Changing Ideas global awards program and Inc. Magazine's annual Best Workplaces list. The company's hybrid workforce is committed to developing innovative solutions for early heart and lung disease detection. This shared vision fuels its employees' passion for creating impactful digital health products.

Key Points: 
  • The company's hybrid workforce is committed to developing innovative solutions for early heart and lung disease detection.
  • "We are proud to win the Inc. Best Workplaces and Fast Company World Changing Ideas awards for the second consecutive year," said Connor Landgraf, Co-founder & CEO of Eko Health.
  • Recognized in the AI and Data category, Eko Health's SENSORA™️ Cardiac Disease Detection Platform was honored by Fast Company.
  • Eko Health has been ranked among the highest-scoring businesses on Inc. Magazine's Best Workplaces list for two years in a row.

The Inner Circle Acknowledges, Doreen Saltiel as a Life Achiever for her contributions to the Healthcare Field.

Retrieved on: 
Wednesday, May 17, 2023
Walter Reed Army Medical Center, Heart, Bachelor of Science in Human Biology, University, Heart failure, Army, Cardiovascular disease, AFI Life Achievement Award, Medicine, Brooke Army Medical Center, Mentorship, New York Medical College, Multimedia, Inner circle, Cardiology, JD, Internal medicine, Valvular heart disease, Pleasure, Dwight D. Eisenhower Army Medical Center, Biology, Brooklyn College, Coronary artery disease, Moyamoya disease, Nursing, Science

LEICESTER, N.C., May 17, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Doreen Saltiel is acknowledged as a Life Achiever for her contributions to the Healthcare Field.

Key Points: 
  • LEICESTER, N.C., May 17, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Doreen Saltiel is acknowledged as a Life Achiever for her contributions to the Healthcare Field.
  • She completed an internship and residency in Internal Medicine at Brooke Army Medical Center in San Antonio, Texas, and a cardiovascular disease fellowship at Walter Reed Army Medical Center.
  • Dr. Saltiel served as the Chief of Cardiology at Eisenhower Army Medical Center and the Army's Southeast Regional Consultant in cardiovascular diseases.
  • Dr. Saltiel has more than 40 years of service in the medical field, but no longer does cardiovascular interventions.

egnite, Inc. Announces Groundbreaking Research from its Database at American College of Cardiology Conference 2023

Retrieved on: 
Sunday, March 5, 2023
Alternative Medicine, Health, Medical Devices, Technology, Practice Management, Software, Cardiology, Mortality, Left ventricular hypertrophy, Teaching, Research, Atrial fibrillation, Patient, Aortic stenosis, Congress, Abstract, American College, Presidential Commission of the Russian Federation to Counter Attempts to Falsify History to the Detriment of Russia's Interests, Valvular heart disease, Pulmonary hypertension, Pharmaceutical industry, Medical device

egnite, Inc. , a leading digital health company for cardiovascular care, announces today two novel research studies were presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with the World Congress of Cardiology (ACC.23/WCC) on March 5, 2023.

Key Points: 
  • egnite, Inc. , a leading digital health company for cardiovascular care, announces today two novel research studies were presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with the World Congress of Cardiology (ACC.23/WCC) on March 5, 2023.
  • The studies were led by renowned cardiologist Philippe Généreux and colleagues using egnite's extensive real-world database of over one million patients from 24 leading teaching and non-teaching institutions across the United States.
  • The first study was recognized as one of the ACC’s top research abstracts in valvular heart disease in 2023.
  • Corresponding two-year treatment rates for moderate-to-severe AS and severe AS were low, at 26.1% and 50.4% respectively

egnite, Inc. Announces A.I. Partnership with Leading Physicians to Elevate the Standard of Care for Patients with Cardiovascular Disease

Retrieved on: 
Monday, February 27, 2023
Technology, Health, Professional Services, Artificial Intelligence, Practice Management, Research, Medical Devices, Software, General Health, Data Analytics, Health Technology, Science, Data Management, Cardiology, Linda, Medicine, Partnership, Algorithm, Standard of care, Valvular heart disease, Patient, Database, MR, Physician, Pharmaceutical industry

egnite , a digital healthcare company, announces a partnership with leading physicians from Morristown’s Gagnon Cardiovascular Institute, Philippe Généreux, a Director of the Structural Heart Program, and Linda Gillam, Chair of Cardiovascular Medicine.

Key Points: 
  • egnite , a digital healthcare company, announces a partnership with leading physicians from Morristown’s Gagnon Cardiovascular Institute, Philippe Généreux, a Director of the Structural Heart Program, and Linda Gillam, Chair of Cardiovascular Medicine.
  • This partnership aims to elevate the standard of care for patients with cardiovascular (CV) disease, which affects an estimated 126 million adults in the U.S.i and is expected to increase by 30% by 2060ii.
  • The partnership will spearhead research initiatives to better understand optimal points of therapeutic intervention for patients with valvular heart disease, using egnite’s flagship digital health platform, CardioCare.
  • This initiative furthers the use of precision medicine algorithms to help physicians design and deliver an individualized patient management plan.

Eko Launches SENSORA™ Cardiac Disease Detection Platform

Retrieved on: 
Thursday, February 23, 2023
ECG, Death, VHD, Cardiovascular disease, University of California, San Francisco, Arrhythmia, ACC, Learning, University, Artificial intelligence, Heart, Heart sounds, Assistant, Algorithm, FDA, Valvular heart disease, Department of Medicine – University of Pamplona, Patient, San Francisco, Heart failure, Economics, Pulmonary hypertension, Division, San Francisco General Hospital, Machine learning, Thrombus, Stethoscope, Length of stay, Stroke, Hospital, Medical device, Nursing, Medical imaging, Cardiology

OAKLAND, Calif., Feb. 23, 2023 /PRNewswire/ -- Eko, a digital health company applying artificial intelligence (AI) in the fight against heart and lung disease, today announced the launch of the SENSORA™ Cardiac Disease Detection Platform. SENSORA™ currently features AI that objectively identifies structural murmurs, a sign of valvular heart disease, and Care Pathway Analytics software that provides downstream visibility and metrics of the patient journey through the healthcare system.

Key Points: 
  • OAKLAND, Calif., Feb. 23, 2023 /PRNewswire/ -- Eko , a digital health company applying artificial intelligence (AI) in the fight against heart and lung disease, today announced the launch of the SENSORA™ Cardiac Disease Detection Platform.
  • SENSORA™ is a cardiovascular disease detection platform that combines the latest advancements in applied machine learning with one of the most ubiquitous medical devices in the world: the stethoscope.
  • By capturing and analyzing heart sounds and electrical signals with its digital stethoscopes, Eko has pioneered a detection platform designed to expand as the company develops applications for additional cardiac conditions.
  • "Our vision for SENSORA™ is to make cardiovascular disease detection simple and accurate in frontline care settings like primary care and urgent care," said Connor Landgraf, Co-founder & CEO of Eko.